D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)
ID: 355242Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is offering the D-START: Data Science Track Award for Research Transition (D/START), a federal grant aimed at supporting innovative research utilizing advanced data science techniques to address substance use and substance use disorders (SUD). This funding opportunity encourages applications from a diverse range of eligible applicants, particularly those from underrepresented groups, and emphasizes the importance of interdisciplinary collaboration in developing effective interventions. Grants of up to $100,000 per year for a maximum of two years are available for well-defined projects that explore novel methodologies, including machine learning, to enhance health outcomes. Interested applicants should note that the application deadlines span from October 2024 to August 2026, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    Files
    Title
    Posted
    The National Institutes of Health (NIH) is offering a funding opportunity titled D-START: Data Science Track Award for Research Transition (D/START), which aims to support research applications utilizing advanced data science techniques for addressing issues related to substance use and substance use disorders (SUD). This small grant program is open to diverse applicants, particularly those from underrepresented groups, and encourages cross-disciplinary collaborations. A total of six to seven awards are expected, providing up to $100,000 per year for a maximum of two years for well-defined research projects. Applications should explore innovative methodologies, including machine learning, to enhance intervention accessibility and efficiency across various health contexts. The application deadlines are set between October 2024 and August 2026, with a focus on creating actionable insights from both new and existing data sources. The program strongly adheres to ethical research standards and requires compliance with NIH’s Data Management and Sharing Policy. This funding initiative highlights the government's commitment to advancing substance use research through innovative data strategies and emphasizes the importance of interdisciplinary approaches to solving pressing health challenges.
    Similar Opportunities
    Imaging - Science Track Award for Research Transition (I/START) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Imaging - Science Track Award for Research Transition (I/START)" aimed at advancing neuroimaging methodologies relevant to substance use disorder (SUD) research. This program encourages both new and established investigators to conduct small "proof-of-concept" studies within a one-year project period, with a funding ceiling of $150,000. The initiative is designed to lower barriers for researchers in adopting advanced imaging techniques, thereby contributing to significant advancements in understanding and addressing substance use challenges. Interested applicants can find more information and application details at the provided link, with the application deadline set for January 7, 2028.
    AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the AIDS-Science Track Award for Research Transition (A-START), a federal grant aimed at supporting early career investigators in the fields of drug use, substance use disorder (SUD), and HIV/AIDS research. This funding opportunity encourages applications for Small Research Grant (R03) projects that can be conducted within a short timeframe and with limited resources, focusing on innovative research that integrates substance use with HIV treatment and prevention strategies. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and tribal governments, with funding available up to $1,000,000 over a project period not exceeding two years. Interested parties should submit their applications by January 7, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    Imaging - Science Track Award for Research Transition (I/START) (R03- Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Imaging - Science Track Award for Research Transition (I/START) grant opportunity, aimed at supporting small research projects in the field of neuroimaging, particularly related to substance use and addiction. This funding initiative encourages both new and established investigators to conduct "proof of concept" studies that can generate pilot data within a short timeframe and with limited resources. Eligible applicants include a diverse range of organizations, such as historically black colleges and universities, tribal governments, and faith-based organizations, with funding of up to $150,000 available for projects lasting a maximum of one year. Interested parties should submit their applications by January 8, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further assistance.
    Imaging - Science Track Award for Research Transition (I/START) (R03- Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Imaging - Science Track Award for Research Transition (I/START) funding opportunity, aimed at supporting small research grants (R03) in the field of neuroimaging, particularly related to substance use and substance use disorders. This initiative encourages both early-career and established researchers to adopt brain imaging methodologies for "proof of concept" studies, which are essential for generating preliminary data necessary for larger research applications. Grants of up to $150,000 are available for a one-year period, with a focus on inclusivity for underrepresented groups among eligible applicants, including various educational institutions and nonprofit organizations. Interested parties should submit their applications by January 8, 2025, and can reach out to the NIH OER Webmaster at grantsinfo@nih.gov for further assistance or inquiries regarding the application process.
    Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)" to support doctoral candidates in completing their dissertation research projects related to substance use disorders. This funding initiative aims to enhance the pool of talented researchers in the field by providing grants of up to $50,000 per year for direct costs over a maximum of two years, with a focus on projects that align with the National Institute on Drug Abuse (NIDA) strategic priorities. Applications are particularly encouraged from individuals who can contribute to diversifying the research workforce, and interested candidates must submit their applications by October 16, 2023, or on February 16 and June 16, 2024. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at supporting innovative research proposals that address the intersection of HIV/AIDS and substance use disorders. This program seeks to fund exceptionally creative scientists who can propose high-impact studies that diverge significantly from existing research paths, with a focus on transformative approaches to prevention and treatment. The grant provides funding of up to $700,000 annually for a maximum duration of five years, with a submission deadline of August 14, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)" aimed at advancing the development of Digital Therapeutics (DTx) for treating Substance Use Disorders (SUDs). This initiative seeks to support the creation of safe and effective clinical-grade digital platforms that can deliver therapeutic treatments, particularly for conditions that currently lack FDA-approved medications. The funding mechanism involves a two-phase cooperative agreement, with the UG3 phase focusing on initial milestones and design testing for up to two years, followed by the UH3 phase, which can extend for an additional three years upon successful completion of the UG3 phase. Eligible applicants include a diverse range of organizations, such as educational institutions, tribal governments, and community-based organizations. The application process opens on February 26, 2024, with multiple deadlines extending through late 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Device Based Treatments for Substance Use Disorders (UG3/UH3 Clinical Trial Optional)" aimed at accelerating the development of innovative devices to treat Substance Use Disorders (SUDs). The initiative seeks proposals that focus on advancing neuromodulatory or neurophysiological devices through various stages of the FDA approval process, with an emphasis on understanding treatment mechanisms and their efficacy. Eligible applicants include a diverse range of organizations, such as academic institutions, nonprofits, and tribal governments, with a maximum budget of $500,000 per year for the UG3 phase, which lasts up to two years before transitioning to the UH3 phase for an additional three years. Applications will open on November 18, 2023, with awards expected to commence by December 2023; interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.